Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
A study to characterise the safety, tolerability and efficacy of LY3962673 in subjects with advanced solid tumors.
Eli Lilly Co.
KRAS G12D-mutant solid tumors.
1 trial -
A study to characterise the safety, tolerability and efficacy of LY4170156 in subjects with advanced solid tumors
Eli Lilly Co.
Ovarian cancer, endometrial cancer, cervical cancer, non-small cell lung cancer, triple-negative breast cancer, pancreatic cancer and colorectal cancer.
1 trial -
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly Co.
Prostatic Neoplasms
1 trial -
EMBER: A Study of LY3484356 in Patients with Breast or Other Non-Breast Cancers
Eli Lilly Co.
Breast Cancer, Endometrial cancer
1 trial -
J1O-MC-JZHD: A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
Eli Lilly Co.
Neuroblastoma
1 trial -
Multiple Ascending Dose Study of LY4256984 in Participants with Sporadic Amyotrophic Lateral Sclerosis
Eli Lilly Co.
Sporadic Amyotrophic Lateral Sclerosis
1 trial -
Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations.
Eli Lilly Co.
Advanced Hematologic Malignancies
1 trial -
Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast Cancer
Eli Lilly Co.
Lung Cancer or Breast Cancer
1 trial -
ADALIMUMAB, BARICITINIB, BARICITINIB, ADALIMUMAB, ETANERCEPT
Eli Lilly Co.
Rheumatoid Arthritis
1 trial -
Omvoh 100 mg solution for injection in pre-filled syringe, Omvoh 100 mg + 200 mg solution for injection in pre-filled syringe, Omvoh 100 mg solution for injection in pre-filled pen, Omvoh 100 mg solution for injection in pre-filled pen, Omvoh 100 mg + 200 mg solution for injection in pre-filled syringe, Omvoh 100 mg solution for injection in pre-filled syringe, Omvoh 100 mg solution for injection in pre-filled pen, Omvoh 100 mg + 200 mg solution for injection in pre-filled pen, Omvoh 100 mg + 200 mg solutio
Eli Lilly Co.
severely active ulcerative colitis (US) and CD (Crohn’s disease)
1 trial -
SELPERCATINIB, SELPERCATINIB
Eli Lilly Co.
Non Small Cell Lung Cancer; Medullary Thyroid Cancer; Colon Cancer; Breast Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Other Solid Tumors With Evidence of Activating RET Alteration;
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources